Wells Fargo analyst Brandon Couillard raised the firm’s price target on Guardant Health (GH) to $120 from $93 and keeps an Overweight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $120 from $85 at Barclays
- GeneDx price target raised to $200, named 2026 Top Pick at BTIG
- Guardant Health price target raised to $140, named 2026 Top Pick at BTIG
- Guardant Health price target raised to $135 from $100 at Citi
- Guardant Health assumed with an Overweight at Morgan Stanley